Nbucky

[Nbucky @Nbucky1]

@MarkKleinmanSky Sounds exciting

[Nbucky @Nbucky1]

Sick Note Britain @LBC @NickFerrariLBC @GBNEWS

https://t.co/J97I2pw02D

[Nbucky @Nbucky1]

#kane must be sleeping with the manager. How is he still playing @EURO2024 @England

[Darren-Uk Trading. @Darrenukdaytra1]

#POLB it’s retraced 1fib and testing the ATH on the weekly. Rsi, Macd and Aroon direction are all positive. Looking good. DYOR

[Poolbeg Pharma @PoolbegPharma]

Last week @PharmaScrip covered the option #POLB signed for an orphan drug candidate for #Behçets Disease.

Read it here:

https://t.co/Ksgyl0lmKU

#raredisease #orphandisease #pharma

[Poolbeg Pharma @PoolbegPharma]

🎉 We received the fully granted patent from the US Patent Office for our Immunomodulator II patent application.

The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication.

https://t.co/EQCMUPphib

#POLB

[Nbucky @Nbucky1]

A company to watch 👀 #EGT #cathalfriel

[European Green Transition @EuropeanGreenT]

Chairman Cathal Friel and CEO Aiden Lavell shared plans in-depth for our latest development in yesterday's @InvestorMeetCo webinar: an exclusive option agreement on a copper tailings recycling project and solar energy scheme in Cyprus.

📺 https://t.co/JMdF1LonjH

#EGT

[Nbucky @Nbucky1]

Poolbeg Pharma plc - Wednesday 1st May 2024 @ 6pm
https://t.co/n4xMjnalyi…

💥 Not one to miss 💥

Sign up and pre-submit questions

@EuropeanGreenT @PoolbegPharma @hVIVO_UK

[Poolbeg Pharma @PoolbegPharma]

Exclusive option to acquire an orphan drug candidate for #Behçets Disease.

☑️Topical Pentoxifylline to treat oral ulcers
☑️FDA Fast Track & Orphan Designation
☑️Positive Phase 2 data
☑️Potential 505(b)(2) regulatory pathway in the U.S.

https://t.co/5WPeNV5K2f

#POLB

[Nbucky @Nbucky1]

This is a company to watch. #polb #PoolbegPharma

[Poolbeg Pharma @PoolbegPharma]

Our CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK:

🤝 Silk Road Therapeutics option agreement
🦠 Behçet's Disease
🔬 Development of tPTX
🧲 Commercial Attraction
👁️ Overview of #POLB full year results

https://t.co/3z2VnGGFPi

[Poolbeg Pharma @PoolbegPharma]

Our CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK:

🤝 Silk Road Therapeutics option agreement
🦠 Behçet's Disease
🔬 Development of tPTX
🧲 Commercial Attraction
👁️ Overview of #POLB full year results

https://t.co/3z2VnGGFPi

[Nbucky @Nbucky1]

Join the chat - Don't miss out.

European Green Transition - Monday 29th April 2024 @ 6pm
https://t.co/TLzm3pwDfG

Poolbeg Pharma plc - Wednesday 1st May 2024 @ 6pm
https://t.co/PSEJUfbwRe

Sign up and pre-submit questions

@EuropeanGreenT @PoolbegPharma @hVIVO_UK

[Eskers 🉐 @Eskers1]

✅Move to new facility in 2024 will ⬆️operational efficiency (as well as capacity).
✅New laboratory offers ability to enhance offering to non-challenge study customers with cutting-edge virology and immunology labs.

[Eskers 🉐 @Eskers1]

✅Product range (# challenge models) ⬆️to 11, fully funded by clients (Such is demand, product development undertaken at 0⃣ cost)
✅Can licence unique infectious disease data for AI analysis (to establish new drug development targets)
✅49% share in ph.3 ready universal flu 💉

[Eskers 🉐 @Eskers1]

✅Looking to use cash mountain to make bolt on acquisitions
✅Is a take over target itself: Current enterprise value to cash profit multiple of 9.1 x & PE ratio of 15.5. (By comparison, Ergomed recently acquired for multiple of 21.1 x & PE ratio of 29.6 based on 2023 forecast)

[Eskers 🉐 @Eskers1]

✅H1 revenue growth of 52% to £27.3m (Excl other income of £1.4m + interest on cash)
✅Weighted contracted order book at £78m (record high) - giving 2024 revenue certainty. Orderbook ⬆️quicker than cash❤️‍🔥
✅FY cash profit estimate of £11m for 2023 and £12.5m for 2024.

[Eskers 🉐 @Eskers1]

#HVO
✅No debt
✅Market Cap £132m (19.5p)
✅Net cash £31.3m (4.6p)
✅Annual dividend
✅Cash profit margin ⬆️to 19.1%
✅FY 2023 revenue guidance ⬆️ to £55m
✅Expanding capacity: 43 beds in 2023 ➡️70 beds in 2024. £4.5m cost 90% funded by clients (such is demand)
🧵👇

[Nbucky @Nbucky1]

Amazing results by #HVO. I really don’t know many, if any, AIM companies that have profit making results like this!

[hVIVO @hVIVO_UK]

Interim Results #HVO

↗️Revenue up 52% = £27.3m
📈EBITDA >doubled = £5.2m
💵Net cash = £31.3m at 30 June
💪FY23 Revenue upgrade = £55m
⬆️ FY23 EBITDA margin upgrade = c.19%
📣Nominal Annual Dividend = details to be announced with FY23 audited results

https://t.co/FxiGALDBoz

[Jarvy55 @Jarvy55]

hVIVO PLC - Interim results #HVO @hVIVO_UK https://t.co/94PrOkqJMP #voxmarkets #investing #shares #RNS via @voxmarkets

[Lumia @BuildOnLumia]

🟣🤝⚫️👀

Orion rebranded the system and soon will rewrite it…

Be there on September 14th.

@okxweb3 #ORN #OKX #Orion #ComingSoon
#BTC #ETH #Crypto #Trading #DeFi
#TOKEN2049